Original Article

The effect of progressive muscle relaxation therapy on diabetes distress & anxiety among people with type 2 diabetes

Manjula Arunraj¹, Vaishnavi Vijay¹, Satyavani Kumpatla¹ & Vijay Viswanathan²

Departments of ¹Psychology, & ²Diabetology, Prof. M. Viswanathan Diabetes Research Centre, Chennai, India

Received August 20, 2024; Accepted November 26, 2024; Ahead of print February 7, 2025; Published February 14, 2025

Background & objectives: Diabetes distress (DD) is a mental condition that can develop in people with diabetes and shares characteristics with stress, anxiety, and depression. The aim was to determine the effect of Jacobson's Progressive Muscle Relaxation (PMR) therapy on DD, anxiety, glycemic control, hemodynamic and lipid measures among people with type 2 diabetes (T2DM).

Methods: A total of 80 participants were recruited for this prospective randomised intervention study and divided into two groups equally; group 1 (Control) (n=40) received general counselling for stress reduction and group 2 (Intervention) (n=40) received PMR therapy and general counselling for stress reduction. A pre-, and post-test was done with diabetes distress Scale (DDS) and generalized anxiety disorder (GAD) Scales. Baseline data on anthropometric, hemodynamic, biochemical details were collected and repeated after three months. Thirty-six participants, with four dropouts in each group, reported for follow up. Diabetes medication regimens in both groups remained unchanged throughout the study period.

Results: There was a significant reduction in the total mean scores of DDS (Pre vs. Post) (3.8 vs. 1.6) and GAD Scale (17.9 vs. 6.3; P<0.0001) in the intervention group. The PMR therapy group showed a significant reduction in HbA1c, fasting and post prandial (PP) glucose levels with HbA1c (baseline vs. follow up; 9.2% vs. 7.6%), fasting (194.5 mg/dl vs. 142.4 mg/dl) and PP glucose levels (266.5 mg/dl vs. 175.5 mg/dl) (P=0.001) whereas control group showed an increase in HbA1c, fasting and PP glucose levels. The impact of PMR therapy was also reflected in the lipid profile. Seventy per cent of the intervention group participants followed PMR therapy regularly.

Interpretation & conclusions: Our study findings highlighted that PMR therapy had a positive effect on diabetes distress and anxiety among people with T2DM. It also improved glycemic control and can be used as an adjunctive to the medications for better management of T2DM.

Key words Anxiety - diabetes distress -glycemic control - Jacobson's PMR therapy - T2DM

Type 2 Diabetes (T2DM) has reached epidemic proportions in India. About one-third of individuals

with diabetes face social, psychological, or both challenges that hinder their ability to self-manage their

^{© 2025} Indian Journal of Medical Research, published by Scientific Scholar for Director-General, Indian Council of Medical Research This open access publication is protected under CC-BY-NC-SA 4.0

condition¹. People with diabetes are prone to distress in their day-to-day lives. Diabetes has a significant influence on both physical and mental health^{2,3}.

Diabetes distress (DD) is characterised by patients' emotional burden about the management of their disease; crucial factors that set distress apart from depression are emotional despair, support, and access to care. DD is the emotional distress caused by living with diabetes and the difficulty of constant daily selfmanagement. Such emotional distress causes stress hormones like cortisol, epinephrine and glucagon to rise, which triggers the sympathetic nervous system. It can be an additional reason for elevated blood glucose levels in individuals with diabetes⁴. DD was reported to be a substantial health issue for adults with T2DM⁵. DD management involves monitoring glucose levels, following a nutrition plan, exercising regularly, and taking proper medications.

Generalized anxiety disorder (GAD) is one of the most common anxiety disorders, with lifetime prevalence rates estimated at 5.7 per cent⁶. Early recognition, and providing appropriate treatment may reduce individual distress, disability status and associated cost of GAD to the society. The prevalence of GAD was higher among people with T2DM than in the general population⁷.

Several non-pharmacological therapies are available such as breathing exercises, thermotherapy, meditation through guided imagery etc., which bring a positive impact on an individual's mind and body. Progressive muscle relaxation (PMR) technique proposed by Dr. Edmund Jacob in 1976 for a duration of 15 min helps people unwind, become more at ease, lessen their anxiety, tension and rage⁸. It uses a gradual, continuous practice approach and thereby reduces the tension and produce a calming effect to the mind⁸. PMR can be used as an adjunctive therapy which is easy to learn, cost effective, and is based on procedures with no side effects.

Screening and treating mood disorders is crucial, as they can negatively impact an individual's wellbeing⁹. PMR has been proven to alleviate anxiety and depression in a variety of illnesses, including asthma¹⁰, pulmonary artery hypertension¹¹, coronary bypass surgery¹², multiple sclerosis¹³, chemotherapy-induced nausea¹⁴. The benefits have been proved on various other disease conditions. However, the impact of Jacobson's PMR on DD, GAD and glycemic control in individuals living with diabetes has not been evaluated. In the Indian context, there isn't much literature available on this topic. Hence, this study was aimed to determine the effect of PMR therapy on diabetes distress and anxiety and also on the glycemic control, hemodynamic, and lipid profile of people with T2DM.

Materials & Methods

This prospective randomised intervention study was conducted by the department of Psychology, Prof. M Viswanathan Diabetes Research Centre, Chennai after obtaining the ethical approval by the Ethics Committee of the Institution. This randomised study screened 578 participants aged 25-60 yr with T2DM from MV Diabetes and Prof. M Viswanathan Diabetes Research Centre for diabetes in north Chennai, India, between July to August 2023 and were followed up till October 2023.

Study design: Out of 578 participants those with HbA1c >10 per cent (n=124), severe complications (n=56), and other serious illnesses (n=12) were excluded and the remaining 386 (209M:177F) participants were screened with Diabetes Distress Scale (DDS)¹⁵ and Generalized Anxiety Disorder (GAD) Scale¹⁶. The participants with DDS score of <3 and with a GAD score of Zero indicated that they did not have DD and Anxiety; hence, they were excluded. The remaining participants were enrolled into two study groups through computer-generated random numbers after screening (Figure). A written informed consent was obtained from all the participants after discussing the benefits and steps of PMR therapy.

Inclusion and exclusion criteria: People with HbA1c between eight per cent and 10 per cent, those who were assessed for DD and anxiety by DDS and GAD Scale and those who had never undergone PMR in the past and were willing to participate in the therapy session were included. People with HbA1c >10 per cent and with severe microvascular complications or any other serious illness were excluded.

Sample size: Forty participants in each group are required to detect a mean difference of 0.8 of HbA1c per cent with 90 per cent power, five per cent precision, and assuming a 20 per cent dropout rate¹⁷.

Study groups: A total of 80 participants were included after screening based on the criteria mentioned above and were enrolled into group 1 (Control group) (n = 40) (M 26:F14) and group 2 (Intervention group) (n = 40) (M 26:F14) and group 2 (Intervention group) (n = 40) (n =




Figure. The flowchart shows the screening and recruitment of the participants, and the procedure followed in the study. DDS, diabetes distress Scale; GAD, generalized anxiety disorder Scale.

40) (M 25:F15) through computer-generated random numbers. After 12 wk, 36 participants from group 1 with four dropouts (2 due to personal reasons,1 due to migration and 1 due to non-response to repeated calls) and 36 participants from group 2 with four dropouts (2 dropouts due to non-adherence to therapy, 2 due to migration and personal reason) reported for follow up. Anthropometric, hemodynamic and biochemical parameters were repeated after three months. The final analysis was carried out with 72 participants. During the study period, the treatment regimen for diabetes remained unchanged in both the study groups (Figure).

Data collection: Data on educational, economic status, hypertension, tobacco use, alcohol consumption, and smoking behaviour, anthropometric measurements like height and weight were collected using a semi-structured questionnaire. Body mass index (BMI) (kg/m²) was calculated. Blood pressure was monitored using a standard mercury sphygmomanometer.

Tools: The DDS is a standardised 17-item self-report measure. The scores for each item range from 1 (no distress) to 6 (severe distress), reflecting the level of distress the respondent experienced in the previous month. This DDS17 yields a total score with four subscale scores, each addressing different kinds of distress. A mean item score of three or more is regarded as a clinically significant level of distress¹⁵. The sevenitem GAD-7 self-report Scale was used to evaluate the key symptoms of generalized anxiety disorder¹⁶. A 4-point Likert-type Scale has been applied to rate the items (0 being not at all and 3 being almost every day). More severe GAD symptoms are indicated by higher scores, which range from 0 to 21.

Methodology: Blood samples were collected, and HbA1c, fasting, postprandial (PP) glucose and lipid levels were measured at baseline and follow up. Baseline data on anthropometric, hemodynamic, and biochemical details were collected and repeated after three months.

Intervention: The group 1 participants were given general counselling for stress reduction and advised to use regular oral hypoglycemic agents (OHA). The group 2 participants were instructed to do PMR by tensing the appropriate muscle group and sustaining the tension for up to 5 sec before relaxing it for 10 sec, along with general counselling and advised to continue the therapy every day with OHA. Both the groups were advised to follow the prescribed diet throughout the study period.

Progressive muscle relaxation therapy: The sequence used in PMR therapy was toes, left foot, left lower leg, left upper leg, and the same sequence for the right leg, hip and buttocks, stomach, chest, shoulders and shoulder blades, back, left hand, left lower arms, and left upper arms, and the same procedure followed for the right hand followed by the neck, forehead, eyes, cheeks, mouth, and jaw. After this, 15 min procedure, the participants were asked to relax in a meditative state for 5 min in the lying position. The whole procedure was taught by the trained psychologist, and a recorded voice version of the therapy was given to each participant for daily practice.

<u>Compliance</u>: The participants were advised to do PMR daily. They were considered as 100 per cent compliant if they did PMR every day. The group 2 participants were joined in a WhatsApp group and asked to drop a done symbol every day after doing the therapy. Weekly therapy sessions were conducted for these participants through video conferencing to motivate them to do the therapy.

Statistical analysis: Per protocol analysis was used and the final analysis was carried out with 72 participants. Mean \pm Standard deviations (SD), number and percentages were reported for continuous and categorical variables, respectively. Chi-square, independent and paired t-test were employed for comparison between and within the groups. A *P* value of <0.05 was considered significant. The analysis was done using SPSS software version 28 (IBM Corp., Armonk, NY, USA).

Results

Table I summarises the baseline characteristics of the study groups. The mean age was similar in both the groups. Sixty-four per cent of the participants in the control and 47 per cent of them in the intervention group completed school-level education. The duration of diabetes was similar in the study groups. Both the study groups were matched for their age and duration of diabetes. The mean age was 50.9 yr in group 1 and 50.1 yr in group 2, respectively. The mean duration of diabetes was 6.7 yr in group 1 and 6.9 yr in group 2. Most of the participants in both groups were from middle-class economic status, followed by uppermiddle-class, and very few respondents were from lower socioeconomic status. Fifty-three per cent from the control and 44 per cent of participants from the intervention group reported walking as a form of physical exercise and following dietary advice. About a third (30.6%) of group 1 participants were on sulphonylureas, 25 per cent used biguanides, and 44.4 per cent used a combination of both, while 33.3 per cent were on sulphonylureas, 16.7 per cent used biguanides and 50 per cent used both in group 2. Nearly 70 per cent participants in the intervention group practiced the PMR therapy regularly and the remaining practiced twice or thrice in a week.

Smoking and alcohol consumption were similar in both groups. The presence of hypertension was significantly higher in group 1 (28%) than in group 2 (8%; P=0.032). Eleven per cent of participants in group 1 and 17 per cent of participants in group 2 were confirmed to have dyslipidemia. Nineteen per cent in both groups had the presence of both hypertension and dyslipidemia.

Table II compares the anthropometric, hemodynamic, and biochemical details of the study groups at baseline and follow up. In both groups, no significant reduction was noted in BMI and systolic blood pressure. No change was noted in diastolic blood pressure in group 1, whereas a significant reduction was noted in group 2 (P=0.001) at follow up.

Both the groups were matched for HbA1c at baseline. The group who received the PMR therapy showed a statistically significant reduction in HbA1c percentage (baseline vs. follow up; 9.2 vs. 7.6), fasting (194.5 vs. 142.4) and PP glucose levels in mg/dl (266.5 vs.175.5; P=0.001). The control group showed an increase in HbA1c, fasting and PP glucose levels. The impact of PMR therapy was also reflected in the lipid profile of the group 2 participants, which showed a significant reduction in lipid parameters like triglycerides, total and LDL cholesterol. HDL cholesterol increased significantly in group 2 (P=0.005). Lipid profile did not show any significant difference in control group except for HDL cholesterol which decreased significantly (P=0.009).

Age in yr (mean \pm SD)50.9 \pm 6.950.1 \pm 7.10Age categories (yr)25-351 (3)1 (3)025-351 (3)1 (3)0036-455 (14)7 (19)0.4046-5519 (53)20 (56)0.0560>5511 (31)8 (22)0.6440Gender0Male25 (69)24 (67)0.0640Female11 (31)12 (33)0.0640Educational status000Primary school4 (11)3 (8)0.1580Secondary school19 (53)14 (39)1.3990Under graduation7 (19)10 (28)0.6930Post graduation6 (17)9 (25)0.7580Duration of diabetes (yr)6.7 \pm 3.66.9 \pm 4.300S000017 (47)15 (42)0.22500>10000017 (47)15 (42)0.22500S000010 (28)3 (8)4.59900Exercise-2 (6)707Yoga1 (3)1 (3)001Malking10 (28)3 (8)4.59900Dyslipidemia7 (19)7 (19)070Sono0010 (28)3 (8)4.59900Dyslipidemia7 (19)7 (19)070Sono0010 (28) </th <th>Variables</th> <th>Group 1 (Control) n=36</th> <th>Group 2 (Intervention-PMR therapy) n=36</th> <th>Chi-square value</th> <th>P value</th>	Variables	Group 1 (Control) n=36	Group 2 (Intervention-PMR therapy) n=36	Chi-square value	P value
Age categories (yr)25-351 (3)1 (3)036-455 (14)7 (19)0.40.046-5519 (53)20 (56)0.0560.0>5511 (3)8 (22)0.6440.0Cender00.0640.0Male25 (69)24 (67)0.0640.0Educational status00.0640.0Primary school4 (11)3 (8)0.1580.0Secondary school19 (53)14 (39)1.3990.0Under graduation6 (17)9 (25)0.7580.0Post graduation6 (17)9 (25)0.7580.0Duration of diabetes (yr)6.7±3.66.9±4.30.0S00004 (11)5 (14)0.1270.0S000015 (42)16 (44)0.0570.0Physical activity15 (42)16 (44)0.550.0Physical activity15 (42)16 (44)0.50.0Vaga19 (53)16 (44)0.50.0Physical activity10 (28)3 (8)4.5990.0Dyslipidemia7 (19)7 (19)00Smoting13 (3)00Comorbidities13 (3)00Smoting13 (3)000Smoting13 (3)000Smoting13 (3)000Smoting13 (3				1	0.627
25.351 (3)1 (3)0 36.45 5 (14)7 (19)0.40. 46.55 19 (53)20 (56)0.0560.056>5511 (31)8 (22)0.6440.Gender0.0640.0640.064Female11 (31)12 (33)0.0640.0640.064Educational status0.0560.0640.064Primary school4 (11)3 (8)0.1580.0640.064Secondary school19 (53)14 (39)1.3990.0Under graduation7 (19)10 (28)0.6930.0Post graduation6 (17)9 (25)0.7580.0Under graduation6 (17)9 (25)0.7580.0So0004 (11)5 (14)0.1270.0So00017 (47)15 (42)0.2250.0Physical activity15 (42)16 (44)0.570.0Physical activity16 (33)16 (44)0.50.0Unotoo17 (47)15 (42)0.4650.0Physical activity10 (28)3 (8)4.5990.0Unotoin10 (28)3 (8)4.5990.0Physterison10 (28)3 (8)4.5990.0Dyslipidemia7 (19)000Sonofiti13 (3)00Comorbidities13 (3)00Sonofiti13 (3)00 <tr< td=""><td></td><td></td><td></td><td></td><td></td></tr<>					
36-45 5 (1) 7 (19) 0.4 0. 46-55 19 (53) 20 (56) 0.056 0. >55 11 (31) 8 (22) 0.644 0. Gender 1 3 (8) 0.064 0. Female 11 (31) 12 (33) 0.064 0. Female 11 (31) 12 (33) 0.064 0. Educational status 0. 0.053 0. 0. Primary school 4 (11) 3 (8) 0.158 0. Secondary school 19 (53) 14 (39) 1.399 0. Under graduation 6 (17) 9 (25) 0.758 0. Duration of diabets (yr) 6 (17) 9 (25) 0.758 0. Sob000 to 10000 17 (47) 15 (42) 0.225 0. >10000 15 (42) 16 (44) 0.57 0. >10000 17 (47) 15 (42) 0.225 0. >10000 17 (47) 15 (42) 0.225 0. >10000 17 (47) 16 (44) 0.5 0. Prysical activity 13 16 (41) 0.127 0. Waling 19 (53) 16 (41) 0.465 0.		1 (3)	1 (3)	0	1
46-55 19 (53) 20 (56) 0.056 0.056 >55 11 (31) 8 (22) 0.644 0.056 Gender 11 (31) 2 (20) 0.064 0.056 Male 25 (69) 24 (67) 0.064 0.056 Female 11 (31) 12 (33) 0.064 0.056 Female 11 (31) 12 (33) 0.064 0.056 Educational status				0.4	0.527
>55 11 (31) 8 (22) 0.644 0. Gender Male 25 (69) 24 (67) 0.064 0. Female 11 (31) 12 (33) 0.064 0. Educational status 12 (33) 0.064 0. Primary school 4 (11) 3 (8) 0.158 0. Secondary school 19 (53) 14 (39) 1.399 0. Under graduation 7 (19) 10 (28) 0.693 0. Post graduation 6 (17) 9 (25) 0.758 0. Duration of diabetes (yr) 6.7±3.6 6.9±4.3 0. 0. Sto000 4 (11) 5 (14) 0.127 0. -50000 to 10000 17 (47) 15 (42) 0.225 0. >100000 16 (24) 0.057 0. Physical activity - 2 (6) - - Walking 19 (53) 16 (44) 0.57 0. Opstipidenia 4 (11) 6 (17) 0.465 <td>46-55</td> <td></td> <td></td> <td>0.056</td> <td>0.813</td>	46-55			0.056	0.813
Gender Male 25 (69) 24 (67) 0.064 0 Female 11 (31) 12 (33) 0.064 0 Educational status 0 0 0 0 0 Primary school 4 (11) 3 (8) 0.158 0 0 Secondary school 19 (53) 14 (39) 1.399 0 0 Under graduation 7 (19) 10 (28) 0.693 0 0 Post graduation 6 (17) 9 (25) 0.758 0 0 Duration of diabetes (yr) 6.73.6 6.94.3 0.127 0 <50000					0.422
Fenale 11 (31) 12 (33) 0.064 0 Educational status 0 Primary school 4 (11) 3 (8) 0.158 0 Secondary school 19 (53) 14 (39) 1.399 0 Under graduation 7 (19) 10 (28) 0.693 0 Post graduation 6 (17) 9 (25) 0.758 0 Duration of diabetes (yr) 6.7 ± 3.6 6.9 ± 4.3 0 0 Monthly family income (INR) 7 (19) 15 (42) 0.225 0 0 < 50000	Gender				
Educational status 00 Primary school 4 (11) 3 (8) 0.158 00 Secondary school 19 (53) 14 (39) 1.399 00 Under graduation 7 (19) 10 (28) 0.693 00 Post graduation 6 (17) 9 (25) 0.758 00 Duration of diabetes (yr) 6.7±3.6 6.9±4.3 00 Monthly family income (INR) 15 (42) 0.225 00 < 50000	Male	25 (69)	24 (67)	0.064	0.8
Primary school 4 (11) 3 (8) 0.158 0.058 Secondary school19 (53)14 (39) 1.399 0.058 Under graduation7 (19)10 (28) 0.693 0.058 Post graduation 6 (17) 9 (25) 0.758 0.058 Duration of diabetes (yr) 6.7 ± 3.6 6.9 ± 4.3 0.127 0.058 Monthly family income (INR) -5 (14) 0.127 0.057 0.057 < 50000 4 (11) 5 (14) 0.057 0.057 < 50000 15 (42) 16 (44) 0.057 0.057 > 100000 15 (42) 16 (44) 0.057 0.057 > 100000 16 (33) $1(3)$ 0 0.057 > 100000 15 (42) 16 (44) 0.057 0.057 > 100000 16 (33) $1(3)$ 0 0.057 > 100000 15 (42) 16 (44) 0.55 0.057 > 100000 16 (33) $1(3)$ 0 0.057 > 100000 $10 (28)$ 3 (8) 4.599 0.057 > 100000 $10 (28)$ 3 (8) 4.599 0.057 > 000000 $10 (28)$ 3 (8) 4.599 0.057 > 000000 $10 (28)$ 3 (8) 4.599 0.057 > 000000 $10 (28)$ 3 (8) 1.03 0.057 > 0000000 $10 (28)$ $3 (8)$ 1.03 0.057 $> 00000000000000000000000000000000000$	Female	11 (31)	12 (33)	0.064	0.8
Secondary school19 (53)14 (39)1.3990.0Under graduation7 (19)10 (28)0.6930.0Post graduation6 (17)9 (25)0.7580.0Duration of diabets (yr) 6.7 ± 3.6 6.9 ± 4.3 0.0Monthly family income (INR) 5 (14)0.1270.0 < 50000 4 (11) 5 (14)0.0570.0 $= 50000$ to 10000017 (47)15 (42)0.2250.0 > 100000 15 (42)16 (44)0.0570.0Physical activity 2 (6) 2 (6) 2 (6) 2 (6)Yoga1 (3)1 (3)0 2 (6) 2 (7)Mypertension10 (28) 3 (8) 4.599 0.0Dyslipidemia4 (11) 6 (17)0.4650.0Hypertension/dyslipidemia7 (19)7 (19)0 2 (2)Smoking 1 (3)1 (3)0 2 (2) 2 (2)Ex-users3 (8)1 (3)1.0590.0Current users1 (3)1 (3)0 2 (2)Ex-users5 (13)4 (11)0.1270	Educational status				0.527
Secondary school 19 (53) 14 (39) 1.399 0.0 Under graduation 7 (19) 10 (28) 0.693 0.0 Post graduation 6 (17) 9 (25) 0.758 0.0 Duration of diabets (yr) 6.7 ± 3.6 6.9 ± 4.3 0.0 Monthly family income (INR) 5 (14) 0.127 0.0 = 50000 4 (11) 5 (14) 0.057 0.0 = 50000 17 (47) 15 (42) 0.225 0.0 > 100000 15 (42) 16 (44) 0.057 0.0 Physical activity - 2 (6) 0.5 0.0 Yaga 1 (3) 1 (3) 0 0 0 Comorbidities - 2 (6) 0.0 0	Primary school	4 (11)	3 (8)	0.158	0.69
Post graduation 6 (17) 9 (25) 0.758 0. Duration of diabetes (yr) 6.7±3.6 6.9±4.3 0. Monthly family income (INR) . . 0. < 50000	Secondary school	19 (53)	14 (39)	1.399	0.236
Duration of diabetes (yr) 6.7±3.6 6.9±4.3 0.0 Monthly family income (INR) 0.127 0.0 < 50000	Under graduation	7 (19)	10 (28)	0.693	0.405
Monthly family income (INR)< 50000	Post graduation	6 (17)	9 (25)	0.758	0.383
< 5000	Duration of diabetes (yr)	6.7±3.6	6.9±4.3		0.847
=50000 to 100000 $17 (47)$ $15 (42)$ 0.225 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 </td <td>Monthly family income (INR)</td> <td></td> <td></td> <td></td> <td></td>	Monthly family income (INR)				
>1000015 (42)16 (44)0.0570.057Physical activityWalking19 (53)16 (44)0.50.055Exercise-2 (6)00Yoga1 (3)1 (3)00Comorbidities10 (28)3 (8)4.5990.055Pypertension10 (28)3 (8)4.5990.055Mypertension/dyslipidemia7 (19)7 (19)0Smoking1 (3)1.0590.055Ex- users3 (8)1 (3)1.0590.055Alcohol consumption1 (3)1 (3)01Ex- users5 (13)4 (11)0.1270	< 50000	4 (11)	5 (14)	0.127	0.721
Physical activity 19 (53) 16 (44) 0.5 0.5 Exercise - 2 (6) 13 0 Yoga 1 (3) 1 (3) 0 13 Comorbidities - - 2 (6) 10 Hypertension 10 (28) 3 (8) 4.599 0.5 Dyslipidemia 4 (11) 6 (17) 0.465 0.5 Hypertension/dyslipidemia 7 (19) 7 (19) 0 0 Smoking - - - 0 0 0 Ex- users 3 (8) 1 (3) 1.059 0.0 0 0 0 Alcohol consumption - - - - 0 <td>=50000 to 100000</td> <td>17 (47)</td> <td>15 (42)</td> <td>0.225</td> <td>0.635</td>	=50000 to 100000	17 (47)	15 (42)	0.225	0.635
Walking 19 (53) 16 (44) 0.5 0.5 Exercise - 2 (6) 2	>100000	15 (42)	16 (44)	0.057	0.811
Exercise - 2 (6) Yoga 1 (3) 1 (3) 0 Comorbidities 1 1 (3) 0 Hypertension 10 (28) 3 (8) 4.599 0. Dyslipidemia 4 (11) 6 (17) 0.465 0. Hypertension/dyslipidemia 7 (19) 7 (19) 0 0 Smoking 1 1 (3) 1.059 0. Current users 3 (8) 1 (3) 0 0 Alcohol consumption 5 (13) 4 (11) 0.127 0.	Physical activity				
Yoga 1 (3) 1 (3) 0 Comorbidities 10 (28) 3 (8) 4.599 0. Dyslipidemia 4 (11) 6 (17) 0.465 0. Hypertension/dyslipidemia 7 (19) 7 (19) 0 0 Smoking 1 (3) 1.059 0. Ex- users 3 (8) 1 (3) 0 0 Alcohol consumption 5 (13) 4 (11) 0.127 0.	Walking	19 (53)	16 (44)	0.5	0.417
Comorbidities 10 (28) 3 (8) 4.599 0. Dyslipidemia 4 (11) 6 (17) 0.465 0. Hypertension/dyslipidemia 7 (19) 7 (19) 0 Smoking 2 2 2 2 Ex- users 3 (8) 1 (3) 1.059 0. Current users 1 (3) 1 (3) 0 2 Alcohol consumption 5 (13) 4 (11) 0.127 0.	Exercise	-	2 (6)		-
Hypertension $10(28)$ $3(8)$ 4.599 0.509 Dyslipidemia $4(11)$ $6(17)$ 0.465 0.509 Hypertension/dyslipidemia $7(19)$ $7(19)$ 0 SmokingEx- users $3(8)$ $1(3)$ 1.059 0.509 Current users $1(3)$ $1(3)$ 0 Alcohol consumptionEx- users $5(13)$ $4(11)$ 0.127 0.509	Yoga	1 (3)	1 (3)	0	1
Dyslipidemia 4 (11) 6 (17) 0.465 0. Hypertension/dyslipidemia 7 (19) 7 (19) 0 Smoking 7 (19) 7 (19) 0 Ex- users 3 (8) 1 (3) 1.059 0. Current users 1 (3) 1 (3) 0 0 Alcohol consumption 5 (13) 4 (11) 0.127 0.	Comorbidities				
Hypertension/dyslipidemia 7 (19) 7 (19) 0 Smoking 1 1 1.059 0. Ex- users 3 (8) 1 (3) 1.059 0. Current users 1 (3) 1 (3) 0 0 Alcohol consumption 5 (13) 4 (11) 0.127 0.	Hypertension	10 (28)	3 (8)	4.599	0.032
Smoking Ex- users 3 (8) 1 (3) 1.059 Current users 1 (3) Alcohol consumption Ex- users 5 (13) 4 (11) 0.127	Dyslipidemia	4 (11)	6 (17)	0.465	0.495
Ex- users 3 (8) 1 (3) 1.059 0. Current users 1 (3) 1 (3) 0 Alcohol consumption 5 (13) 4 (11) 0.127 0.	Hypertension/dyslipidemia	7 (19)	7 (19)	0	1
Current users 1 (3) 0 Alcohol consumption 1 (3) 0 Ex- users 5 (13) 4 (11) 0.127 0.127	Smoking				
Alcohol consumption Ex- users 5 (13) 4 (11) 0.127 0.	Ex- users	3 (8)	1 (3)	1.059	0.303
Ex-users 5 (13) 4 (11) 0.127 0.	Current users	1 (3)	1 (3)	0	1
	Alcohol consumption				
Current users $2(6)$ $3(8)$ 0.215 0	Ex- users	5 (13)	4 (11)	0.127	0.722
	Current users	2 (6)	3 (8)	0.215	0.643

Table III shows the mean item scores of the DDS and GAD-7 within the study groups. The scores of four subscales of DDS: emotional, physician-related, regimen-related, and interpersonal distress were significantly decreased at follow up in group 2 participants as compared to baseline and a significant decrease was also noted in the total score of DDS (3.8 vs. 1.6) and GAD Scale (17.9 vs. 6.3) (P<0.0001)

among the participants who followed the PMR therapy. In group 1 participants, the emotional, interpersonal and regimen-related distress scores showed a minimal increase in the follow up mean scores, whereas physician-related distress showed a minimal decrease among the participants. The total scores of DDS (3.9 vs. 4.4; P=0.001) and GAD Scale (17.4 vs. 18.6; P=0.015) showed a significant increase in group 1 participants.

Table	II. Comparisor	Table II. Comparison of anthropometric, haemodynamic and biochemical details of the study groups at baseline and follow up visit	tric, haemo	odynamic a	and biochemical	details of the s	tudy group	os at baselir	ie and follc	w up visit		
Characteristics	0	Group 1 (control) n=36) n=36		Group 2 (It	Group 2 (Intervention-PMR therapy) n=36	R therapy)) n=36	Comp	Comparing between the groups	sen the gro	sdn
	Baseline	Follow up	t value	P value	Baseline	Follow up	t value	P value	Baseline	aline	Follow up	dn v
	(mean±SD)	(mean±SD)			(mean±SD)	(mean±SD)			t value	P value	t value	P value
BMI (Kg/m ²)	27.5±3.4	27.7±3.5	1.07	0.237	27.1±4.3	27.2±4.4	0.33	0.517	0.50	0.55	0.54	0.562
Systolic BP (mm/Hg)	122.2 ± 12.1	121.7 ± 11.9	0.73	0.561	122.4 ± 9.9	121.4 ± 3.5	0.76	0.576	0.09	0.649	0.13	0.936
Diastolic BP (mm/Hg)	73.8±7.7	74.4±6.4	0.66	0.377	75.2±7.5	71.1 ± 3	3.68	0.001	0.78	0.647	2.83	0.004
HbA1c(%)	$9.0 {\pm} 0.8$	$9.4{\pm}1.3$	2.14	0.063	9.2±0.5	7.6 ± 1.1	8.69	0.001	1.16	0.140	6.34	0.001
Fasting glucose (mg/dl)	165.6 ± 53.4	176.3 ± 50.6	1.43	0.216	194.5±47.8	142.4±45.7	6.73	0.001	2.42	0.016	2.98	0.003
PP glucose (mg/dl)	227.5±74.9	238.3±72.4	0.98	0.363	266.5 ± 71.4	175.5 ± 63.9	7.59	0.001	2.26	0.017	3.9	0.001
Total cholesterol (mg/dl)	145.6 ± 35.7	149.2 ± 48.6	0.64	0.681	173.0±52.6	157.1 ± 34.5	1.91	0.087	2.59	0.027	0.79	0.386
LDL cholesterol (mg/dl)	74.6±25.2	78.6±32.7	0.92	0.521	85.6±28.9	78.7±23.5	1.31	0.228	1.72	0.102	0.02	0.735
HDL cholesterol (mg/dl)	47.1±7.7	43.8±9.4	2.73	0.009	48.1±7.5	50.6±7.7	2.97	0.005	0.56	0.844	3.33	0.004
Triglycerides (mg/dl)	129.3 ± 50.9	133.9 ± 56.1	0.57	0.309	165.9 ± 92	123.5±57.4	3.91	0.001	2.09	0.123	0.78	0.275
Values are mean±SD. BMI, body mass index; BP, blood	ody mass index;	BP, blood pressu	re; PP, pos	t prandial; I	DL, low density	pressure; PP, post prandial; LDL, low density lipoprotein; HDL, high density lipoprotein)L, high de	nsity lipopre	otein			

Table IV compares the mean difference of DDS and GAD-7 scores between the baseline and follow up visit in emotional burden, physician-related, regimenrelated, interpersonal distress. Total DDS score was significantly different in group 2 when compared to group 1.The mean difference score of GAD between the groups was also statistically significant, with a greater reduction in group 2 (P=0.001). Overall, there was a greater reduction in the total DD score and anxiety disorder score in the participants of the PMR therapy group. Seventy per cent participants in group 2 followed PMR therapy everyday and the remaining 30 per cent followed six days per week. Out of the 40 participants all joined the weekly therapy sessions for 10 wk, two were absent for the 11th wk and three were absent for the 12th wk but they continued their regular therapy practice.

Discussion

People living with diabetes are more likely to experience stress because of the anguish of their disease. This condition leads to DD and anxiety. This study helped to determine the effectiveness of PMR therapy on DD and anxiety among people with T2DM. Numerous measurements such as anthropometric, lipid, hemodynamic parameters and glycemic control were used to evaluate the effectiveness of the therapy. This study also examined the impact of PMR therapy along with medications on the above parameters and demonstrated an encouraging impact on a number of outcome indicators. The findings illustrated that consistent practice of PMR therapy combined with conventional medication showed a significant improvement in glycemic control, and reduction in lipid and hemodynamic parameters. There was a greater reduction noted in the total DD and anxiety scores among those who followed the PMR therapy. Similar educational backgrounds and having identical socioeconomic status, BMI, age, glycemic status, and duration of diabetes between the study groups prevented confounding effect on intervention outcomes. Using a successful follow up strategy of sending daily messages through WhatsApp groups and making phone calls, our study yielded a response rate of 90 per cent. In our study, the impact of PMR therapy was most apparent in relation to glycemic status and the decrease in diabetes distress and anxiety scores. More than 70 per cent of the participants in the intervention group practised PMR therapy regularly to achieve favourable outcomes.

Group 1 (control) n=36 Group 2 (Intervention-PMR therapy) n) n=36	
Baseline (mean±SD)	Follow up (mean±SD)	t value	P value	Baseline (mean±SD)	Follow up (mean±SD)	t value	P value
5.1±0.7	5.5±0.4	4.54	0.001	4.8±0.9	1.8±0.6	20.9	0.001
1.3±0.6	$1.2{\pm}0.6$	2.77	0.008	1.3±0.4	1.0±0.2	3.81	0.001
4.8±0.6	5.0 ± 0.6	2.47	0.023	4.4±1.1	4.3±1	3.4	0.003
3.1±1.1	3.6±1.2	5.48	0.001	3.2±4.1	1.5 ± 0.6	2.57	0.001
3.9±0.6	4.4 ± 0.7	7.01	0.001	3.8±0.6	1.6±0.5	27.28	0.001
17.4±3	18.6±2.6	2.33	0.015	17.9±2.6	6.3±3.3	19.05	0.001
((mean±SD) 5.1±0.7 1.3±0.6 4.8±0.6 3.1±1.1 3.9±0.6	(mean \pm SD)(mean \pm SD)5.1 \pm 0.75.5 \pm 0.41.3 \pm 0.61.2 \pm 0.64.8 \pm 0.65.0 \pm 0.63.1 \pm 1.13.6 \pm 1.23.9 \pm 0.64.4 \pm 0.7	$(mean\pm SD)$ $(mean\pm SD)$ 5.1 ± 0.7 5.5 ± 0.4 4.54 1.3 ± 0.6 1.2 ± 0.6 2.77 4.8 ± 0.6 5.0 ± 0.6 2.47 3.1 ± 1.1 3.6 ± 1.2 5.48 3.9 ± 0.6 4.4 ± 0.7 7.01	(mean \pm SD)(mean \pm SD)5.1 \pm 0.75.5 \pm 0.44.540.0011.3 \pm 0.61.2 \pm 0.62.770.0084.8 \pm 0.65.0 \pm 0.62.470.0233.1 \pm 1.13.6 \pm 1.25.480.0013.9 \pm 0.64.4 \pm 0.77.010.001	(mean±SD)(mean±SD)(mean±SD) 5.1 ± 0.7 5.5 ± 0.4 4.54 0.001 4.8 ± 0.9 1.3 ± 0.6 1.2 ± 0.6 2.77 0.008 1.3 ± 0.4 4.8 ± 0.6 5.0 ± 0.6 2.47 0.023 4.4 ± 1.1 3.1 ± 1.1 3.6 ± 1.2 5.48 0.001 3.2 ± 4.1 3.9 ± 0.6 4.4 ± 0.7 7.01 0.001 3.8 ± 0.6	(mean±SD)(mean±SD)(mean±SD)(mean±SD) 5.1 ± 0.7 5.5 ± 0.4 4.54 0.001 4.8 ± 0.9 1.8 ± 0.6 1.3 ± 0.6 1.2 ± 0.6 2.77 0.008 1.3 ± 0.4 1.0 ± 0.2 4.8 ± 0.6 5.0 ± 0.6 2.47 0.023 4.4 ± 1.1 4.3 ± 1 3.1 ± 1.1 3.6 ± 1.2 5.48 0.001 3.2 ± 4.1 1.5 ± 0.6 3.9 ± 0.6 4.4 ± 0.7 7.01 0.001 3.8 ± 0.6 1.6 ± 0.5	(mean±SD)(mean±SD)(mean±SD)(mean±SD) 5.1 ± 0.7 5.5 ± 0.4 4.54 0.001 4.8 ± 0.9 1.8 ± 0.6 20.9 1.3 ± 0.6 1.2 ± 0.6 2.77 0.008 1.3 ± 0.4 1.0 ± 0.2 3.81 4.8 ± 0.6 5.0 ± 0.6 2.47 0.023 4.4 ± 1.1 4.3 ± 1 3.4 3.1 ± 1.1 3.6 ± 1.2 5.48 0.001 3.2 ± 4.1 1.5 ± 0.6 2.57 3.9 ± 0.6 4.4 ± 0.7 7.01 0.001 3.8 ± 0.6 1.6 ± 0.5 27.28

 Table IV. Comparison of mean difference of DDS and GAD-7

 anxiety Scale scores between the study groups

Characteristics	Group 1 (control) n=36;	Group 2 (intervention- PMR therapy)	P value
	(mean±SD)	1.57	
Emotional burden	0.4±0.6	-3.0±0.9	0.001
Physician related distress	-0.1±0.2	-0.2±0.4	0.061
Regimen related distress	0.2±0.4	-0.1± 0.2	0.001
Interpersonal distress	0.5±0.5	-1.7±4.1	0.001
Diabetes distress Scale total score	0.5±0.4	-2.1±0.5	0.001
Generalized anxiety disorder Scale total score	1.3±3.2	-11.6±3.7	0.001
Values are mean±S	D		

Our findings were consistent and similar to the previous reports from other populations^{18,19}. A very recent study from Indonesia showed that PMR reduced stress and glucose levels in people with T2DM. The authors suggested that Jacobson's PMR approach could help individuals with diabetes reduce stress, anxiety, and depression while also promoting sustainable stress prevention strategies¹⁹. PMR can also reduce sadness, anxiety, stress, and glucose levels and improve quality of life. The study done in Egypt showed a remarkable difference in DD and anxiety among the study participants²⁰. Also, PMR technique was found to be effective in reducing depression in people with diabetes²¹, supporting the evidence generated from our

study. PMR may reduce anxiety and depression by regulating the central and peripheral nervous systems, potentially blocking physiological and psychological responses to anxiety.

Our study findings showed promising results on the effect of PMR therapy in reducing glucose levels, HbA1c and lipid parameters. Similarly, in another study, the PMR technique and a structured exercise programme were effective in reducing HbA1c in individuals with T2DM. The study conducted in Indonesia also proved the effectiveness of progressive relaxation in reducing glucose levels¹⁸. Another study in older people, suggested that the use of evidencebased complementary therapies in general health care services may enhance quality care and promote positive health care service delivery²². Our study findings contrast with the research conducted in Iran, which indicated that PMR had no impact on glycemic control and quality of life in individuals with T2DM²³.

The effectiveness of PMR therapy was evident from the above studies. In one of our previous reports, it was proved that women had high levels of distress in managing diabetes as compared to men⁴. This study used the same DDS-17 item Scale to assess DD. It was reported that 55 per cent of women had moderate to high diabetes related distress on DDS-17 Scale⁴. Women may be targeted and guided to practice PMR in order to reduce DD and anxiety. Another study conducted on Indian population reported the prevalence of DD as 42 per cent and it was significantly and negatively associated with the domains of self-management such as dietary control, glucose management and health care use²⁴. One of the recent studies from eastern India also showed a high prevalence of DD in 77 per cent participants and emotional distress was more common²⁵.

In our study, there were no adverse events reported and few participants from the intervention group participated enthusiastically in the therapy session and mentioned that they experienced a calm and peaceful attitude. This anti-stress benefit of PMR therapy may contribute to greater control over their glucose levels. The limitations of the study were as follows: the sample size was small and the findings of this study have to be confirmed by further evaluating the effect of PMR therapy in a larger sample. It is also necessary to assess the long-term sustainability of PMR therapy's effect on glycemic control, DD and anxiety. The study was conducted in a single centre, thus restricting the generalizability of the findings.

Overall, the findings in this study suggested that PMR therapy had a positive effect on diabetes distress and anxiety among people with T2DM. The study indicates that PMR can enhance their glycemic control. Therefore, regular use of PMR therapy in conjunction with conventional medications may be advantageous for better diabetes management and improve the quality of life of people with T2DM. This can be implemented by reinforcing the practice of PMR therapy for all people with T2DM at every follow up visit.

Financial support & sponsorship: None.

Conflicts of Interest: None.

Use of Artificial Intelligence (AI)-Assisted Technology for manuscript preparation: The authors confirm that there was no use of AI-assisted technology for assisting in the writing of the manuscript and no images were manipulated using AI.

References

- Grigsby AB, Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. Prevalence of anxiety in adults with diabetes: A systematic review. *J Psychosomatic Res* 2002; 53: 1053-60.
- 2. Robinson DJ, Coons M, Haensel H, Vallis M, Yale JF. Diabetes and mental health. *Can J Diabetes* 2018; *42* : S130-41.
- 3. Falco G, Pirro PS, Castellano E, Anfossi M, Borretta G, Gianotti L. The relationship between stress and diabetes mellitus. *J Neurol Psychol* 2015; *3* : 7.
- Hemavathi P, Satyavani K, Smina TP, Vijay V. Assessment of diabetes related distress among subjects with type 2 diabetes in South India. *Int J Psy Counselling* 2019; 11: 1-5.
- 5. Islam MR, Karim MR, Habib SH, Yesmin K. Diabetes distress among type 2 diabetic patients. *Int J Med Biomedical Res* 2013; *2* : 113-24.
- 6. Simon NM, Parker SW, Wernick-Robinson M, Oppenheimer JE, Hoge EA, Worthington JJ, et al. Fluoxetine for

vestibular dysfunction and anxiety: a prospective pilot study. *Psychosomatics* 2005; *46* : 334-9.

- Huang CJ, Hsieh HM, Tu HP, Jiang HJ, Wang PW, Lin CH. Generalized anxiety disorder in type 2 diabetes mellitus: Prevalence and clinical characteristics. *Braz J Psychiatry* 2020; 42: 621-9.
- Jacob S, Sharma S. Efficacy of progressive muscular relaxation on coping strategies and management of stress, anxiety and depression. *Int J Indian Psychology* 2018; 6 : 106-24.
- Bartholomew JB, Morrison D, Ciccolo JT. Effects of acute exercise on mood and well-being in patients with major depressive disorder. *Med Sci Sports Exerc* 2005; 37: 2032-7.
- Nickel C, Kettler C, Muehlbacher M, Lahmann C, Tritt K, Fartacek R, *et al.* Effect of progressive muscle relaxation in adolescent female bronchial asthma patients: A randomized, double-blind, controlled Study. *J Psychosomatic Res* 2005; 59: 393-8.
- Li Y, Wang R, Tang J, Chen C, Tan L, Wu Z, et al. Progressive muscle relaxation improves anxiety and depression of pulmonary arterial hypertension patients. Evid Based Complement Alternat Med 2015; 2015 : 792895.
- 12. Dehdari T, Heidarnia A, Ramezankhani A, Sadeghian S, Ghofranipour F. Effects of progressive muscular relaxation training on quality of life in anxious patients after coronary artery bypass graft surgery. *Indian J Med Res* 2009; *129* : 603-8.
- Ghafari S, Ahmadi F, Nabavi M, Anoshirvan K, Memarian R, Rafatbakhsh M. Effectiveness of applying progressive muscle relaxation technique on quality of life of patients with multiple sclerosis. *J Clin Nurs* 2009; *18* : 2171-9.
- 14. Tian X, Tang RY, Xu LL, Xie W, Chen H, Pi YP, et al. Progressive muscle relaxation is effective in preventing and alleviating of chemotherapy-induced nausea and vomiting among cancer patients: a systematic review of six randomized controlled trials. *Support Care Cancer* 2020; 28: 4051-58.
- Fisher L, Hessler DM, Polonsky WH, Mullan J. When is diabetes distress clinically meaningful? Establishing cut points for the diabetes distress scale. *Diabetes Care* 2012; 35 : 259-64.
- Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch Intern Med 2006; 166: 1092-7.
- Trimurthula SR, Perakam S, Kondapalli A. The effect of Jacobson's progressive muscle relaxation technique along with structured exercise program on Hba1c in type II diabetes mellitus patients. *Int J Health Sci Res* 2020; 10: 28-34.
- Avianti N, Desmaniarti Z, Rumahorbo H. Progressive muscle relaxation effectiveness of the blood sugar patients with type 2 diabetes. *Open Journal of Nursing* 2016; 6 : 248-54.
- Rumaolat W, Rumaolat W, Sely MD. The effect of progressive muscle relaxation on reducing stress and blood sugar in type 2 diabetes mellitus patients in the work area of Taniwel Public Health Center. *Int J Med Health* 2022; 1: 97-106.

- Ebrahem SM, Masry SE. Effect of relaxation therapy on depression, anxiety, stress and quality of life among diabetic patients. *Clin Nurs Stud* 2017; 5:35.
- Perakam S, Devpura G, Manohar S, Kondapalli A. The effect of Jacobson's progressive muscle relaxation technique on depression in diabesity patients. *Int J Health Sci Res* 2019; 9: 34-41.
- 22. Khakha DC, Satapathy S, Dey AB. Impact of Jacobson progressive muscle relaxation (JPMR) and deep breathing exercises on anxiety, psychological distress and quality of sleep of hospitalized older adults. *J Psy Res* 2015; *10* : 211-23.
- 23. Ghezeljeh TN, Kohandany M, Oskouei FH, Malek M. The effect of progressive muscle relaxation on glycated hemoglobin and health-related quality of life in patients with type 2 diabetes mellitus. *Applied Nursing Res* 2017; *33* : 142-8.
- 24. Patra S, Patro BK, Padhy SK, Mantri J. Prevalence of diabetes distress and its relationship with self-management in patients with type 2 diabetes mellitus. *Industrial Psy J* 2021; *30* : 234-9.
- 25. Mahala S, Basu G, Halder I. Burden and predictors of distress among persons with type 2 diabetes mellitus: Excerpts of an observational study from Eastern India. *J Family Med Prim Care* 2024; 13: 1042-8.

For correspondence: Dr Vijay Viswanathan, Department of Diabetology, Prof. M. Viswanathan Diabetes Research Centre, Chennai 600 013, Tamil Nadu, India e-mail: drvijay@mvdiabetes.com

80